US Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market Analysis

US Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market Executive Summary

The US Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market was valued at $7.6 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 5.1% from 2022 to 2030 and will reach $11.4 Bn in 2030. Chronic obstructive pulmonary disease (COPD) is a chronic condition characterized by shortness of breath, cough, and sputum production. While signs of the disease do not commonly develop in those under the age of 55, lung alterations begin many years earlier. COPD is a catch-all term for a variety of respiratory disorders, including chronic bronchitis and emphysema. COPD deteriorates gradually over time. More frequent exacerbations, additional reductions in airflow, and earlier death are all connected with increasing disease severity. Shortness of breath limits people's activity levels and lowers their quality of life as the disease progresses.

Many people take their breathing for granted. In the US, however, 3.8 Mn people over the age of one have asthma, and 2.0 Mn have chronic obstructive pulmonary disease (COPD), both of which can impair a person's capacity to breathe. People suffering from asthma or COPD may find it difficult to participate in daily life, school, work, and social activities. There is also a collective consequence in terms of missed productivity and healthcare expenses, especially given the rising prevalence of both asthma and COPD.

Market Dynamics

Market Growth Drivers

The prevalence of COPD in the United States is on the rise, with an estimated 16 Mn adults diagnosed with the condition. This trend is expected to continue due to factors such as an aging population and the continued use of tobacco products. The prevalence of COPD in the US is expected to increase from 6.2% in 2020 to 6.8% by 2028. There is a growing awareness of COPD among patients and healthcare professionals, leading to earlier diagnosis and treatment. This trend is supported by increased public health campaigns, as well as improvements in diagnostic tools and techniques. There have been significant advancements in the treatment of COPD, including new medications and therapies that can improve lung function and reduce symptoms. For example, the introduction of biological therapies for COPD has shown promising results, with medications such as dupilumab and benralizumab showing efficacy in clinical trials.

The COPD treatment market is expected to grow at a CAGR of 4.7% from 2021 to 2028. The use of digital health technologies, such as telemedicine and remote monitoring, is on the rise in the management of COPD. These technologies allow for more frequent and accurate monitoring of symptoms, as well as improved communication between patients and healthcare providers. According to a report, the global digital health market for COPD is expected to grow at a CAGR of 12.5% from 2020 to 2027.

Market Restraints

There is a lack of comprehensive data on the prevalence and incidence of COPD in the US, which can make it difficult to accurately assess the market size and potential growth opportunities. Additionally, there is a lack of standardized data collection and reporting methods, which can make it difficult to compare data across different studies and regions. COPD is a heterogeneous disease, with patients exhibiting a wide range of symptoms and responses to treatment. This variability can make it difficult to develop effective treatments and can lead to challenges in clinical trial design and data interpretation.

The development and approval of new COPD treatments can be a lengthy and costly process, with many regulatory hurdles to overcome. The high cost of developing new treatments, coupled with the relatively small patient population, can make it challenging for companies to bring new products to market. COPD is a significant economic burden on patients, healthcare systems, and society as a whole. The high cost of COPD treatment, including medications, oxygen therapy, and hospitalizations, can be a major barrier to access for patients. Additionally, COPD-related morbidity and mortality can result in lost productivity and increased healthcare costs.

Competitive Landscape

Key Players

• GlaxoSmithKline
• Astellas Pharma
• AstraZeneca
• Boehringer Ingelheim Pharmaceuticals
• Novartis
• Pfizer
• Teva US Limited
• ResMed
• Hill-Rom

Notable Deals

In 2019, GSK and Pfizer completed a joint venture to combine their consumer healthcare businesses, which included several COPD treatments such as Advair, Breo Ellipta, and Spiriva.

Healthcare Policies and Regulatory Landscape

The Healthcare policy for the US COPD market is primarily overseen by the US Food and Drug Administration (FDA), which is responsible for evaluating and approving new therapies for the treatment of COPD. The FDA's Center for Drug Evaluation and Research (CDER) is responsible for reviewing and approving new drug therapies, while the Center for Devices and Radiological Health (CDRH) is responsible for reviewing and approving medical devices used in the treatment of COPD. The FDA requires pharmaceutical companies to submit detailed data on the safety and efficacy of new drug therapies for the treatment of COPD. This includes data from preclinical and clinical trials, as well as information on manufacturing and labeling. The FDA reviews this data to determine whether the new therapy is safe and effective for use in the treatment of COPD.

Overall, the regulatory policy for the US COPD market is designed to ensure that new therapies are safe and effective for use in the treatment of COPD and that patients have access to accurate information about the therapies they are using. This regulatory framework is critical for ensuring the quality and safety of care for patients with COPD.

Reimbursement Scenario

Medicare is a federal health insurance program for people over the age of 65 and people with certain disabilities. Medicare reimburses healthcare providers for a wide range of COPD-related services, including hospitalizations, physician visits, and prescription drugs. Reimbursement rates are set by the Centers for Medicare and Medicaid Services (CMS) and can vary depending on the type of service and the geographic region. Whereas, Medicaid is a joint federal-state program that provides healthcare coverage to low-income individuals and families. Medicaid reimbursement rates vary by state and can be lower than the rates paid by private insurers. However, Medicaid is an important source of coverage for many people with COPD who cannot afford private insurance.

Private health insurance is often provided by employers, but can also be purchased on the individual market. Private insurers negotiate reimbursement rates with healthcare providers, and these rates can vary depending on the type of service and the geographic region. Private insurance plans also vary in terms of copays, deductibles, and out-of-pocket maximums that patients are responsible for paying.